Discontinued Hostess snacks have been piling up for decades — from Chocodiles to Choco-Bliss to the Sweet Rolls that Hostess ...

Rhythm Heaven Groove's base single player challenge consists of eight stages that introduce all sorts of rhythms and ...

Eli Lilly is having a Total Recall moment, using cutting-edge technology to bring real, undocumented memories to life as it looks to boost awareness of Alzheimer’s disease. There’s no dystopian 2084 ...

Maureen Fitzsimmons of Moosic won Best in Show at the Electric City Flower Show on Saturday for her water lily. The annual show drew a big crowd to the grounds of the Everhart Museum in Nay Aug Park, ...

"Lily thought the show was going to be an authentic chance at finding love, but it turned out to be a total joke." While it appeared Lily got fed up of Ally and Dylan’s connection, especially when it ...

Recently, we came across a crowd-friendly 9x13 dessert made with milk’s favorite cookie, and if you're in search of a potluck dish that will steal the show, you'll want to bookmark this one ASAP. Oreo ...

Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks. Lilly is obtaining the ...

Eli Lilly's Jacob Van Naarden says Lilly is using the financial strength from its GLP-1 drugs like Mounjaro and Zepbound to fund its new dealmaking strategy. Van Naarden recently became Lilly's head ...

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major ...

LimmaTech's lead program targets S. aureus, a major cause of surgical-site infections Vaccine Company acquisition includes experimental vaccine for Epstein-Barr virus Curevo is developing shingles ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Eli Lilly said Tuesday it would buy ...

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal ...